About The Company
In the ever-evolving world of healthcare, innovative companies are constantly emerging with groundbreaking solutions to address the most pressing challenges faced by medical professionals and patients alike. Enter: Kephera Diagnostics, a pioneering company at the forefront of diagnostic technology. With their unwavering commitment to improving patient outcomes, Kephera Diagnostics is revolutionizing the way we approach healthcare.
At the core of Kephera Diagnostics’ mission is the development of accurate, reliable, and accessible diagnostic tools that aid in the early detection and monitoring of diseases. By leveraging advanced immunological and molecular techniques, the company is developing a diverse portfolio of diagnostic tests that cater to a wide range of medical conditions. These tests not only provide faster and more precise results but also offer insights that enable healthcare professionals to make informed treatment decisions.
One of the key areas of focus for Kephera Diagnostics is emerging and neglected infectious diseases. With the global pandemic highlighting the ongoing threat of newly emerging pathogens, the company has been at the forefront of developing innovative diagnostic methods to enable a faster public health response. Kephera Diagnostics is currently developing an ultra-rapid point-of-care testing platform that will enable assay developers to quickly transition new tests from the lab to scaled up manufacturing and delivery to the field, wherever needed.
In May 2023, Kephera Diagnostics received a $3 million Phase II SBIR grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases. The grant will be used to develop and clinically validate a point-of-care test for neurocysticercosis, a potentially fatal infection of the central nervous system caused by the tapeworm Taenia solium, which accounts for one third of the world’s epilepsy cases. The test aims to differentiate neurocysticercosis from other causes of seizures in patients with epileptic-like symptoms. “[The grant] confirms the validity of our methodology and approach and will enable us to advance the test through clinical trials and to make it available commercially, where we believe it will fill an important gap in the diagnosis and treatment of patients presenting with seizures worldwide,” said Kephera Diagnostics CEO Andrew Levin in a recent statement.
Wolf Greenfield & Kephera Diagnostics
Wolf Greenfield has worked with Kephera to provide strategic intellectual property advice aimed at protecting Kephera’s innovations and positioning them for an advantageous position in the marketplace. Wolf Greenfield is also proud to have drafted and filed the first patent applications in Kephera’s name.
